K.G. Jebsen Center for for Myeloid Blood Cancer

Cancer affects approximately 30,000 people in Norway each year, and more than 10 million people worldwide die from cancer each year. Cancer is now the leading cause of death globally and is increasing rapidly with increasing life expectancy. Treatment for most aggressive cancers is inadequate. Patients who start treatment for blood cancer such as acute myeloid leukemia usually receive standard therapy that does not always work on the patient’s cancer cells, but doctors do not discover this until a few weeks later. The main goal of the new K.G. Jebsen Center for Myeloid Blood Cancer (CMYC) is to develop diagnostics at the single-cell level that reveals response to treatment after hours and days, and use this information to optimize or replace the planned treatment. The researchers want to develop diagnostics and treatment that closely follows the individual cancer cell. At the same time, information can be obtained about other cells, immune cells and support cells that affect the treatment effect. Overall, one will then have information at the cellular level about the individual patient, which will allow for more accurate and dynamic tailoring of treatment.